Compare · GLP-1 agonist
Ecnoglutide vs Retatrutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Ecnoglutide | Retatrutide | |
|---|---|---|
| Evidence | 7/10 | 7/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A long-acting, cAMP-biased GLP-1 receptor agonist approved in China for type 2 diabetes and weight management, with genuine peer-reviewed Phase 3 data that is still confined to Chinese populations and not FDA-approved. | An investigational triple-hormone agonist with striking weight-loss data in trials, but not yet FDA-approved and with no peer-reviewed Phase 3 results. |
| Full profile → | Full profile → |
Ecnoglutide
Ecnoglutide (its development name is XW003) is an injectable drug for type 2 diabetes and weight loss. It belongs to the same broad family of medicines as semaglutide — the GLP-1 receptor agonists (drugs that copy a natural gut hormone to lower blood sugar and curb appetite). Two things make it…
Retatrutide
Retatrutide (Lilly's lab code LY3437943) is an experimental injectable drug being studied for obesity and type 2 diabetes. It has shown some of the biggest weight-loss numbers seen in any trial so far. But as of June 2026 it is not approved anywhere, and the big Phase 3 results that matter most…